Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.
Torrente-Segarra V, Fernandez Prada M, Expósito Moliner R, Garrido Puñal NP, Sánchez-Andrade Fernández A, Lamua Riazuelo JR, Olivé A, Tovar Beltrán JV; RENACER Study Group (REgistro NAcional CERtolizumab). Torrente-Segarra V, et al. Rheumatol Int. 2019 Feb;39(2):395-398. doi: 10.1007/s00296-018-4205-z. Epub 2018 Nov 24. Rheumatol Int. 2019. PMID: 30474721 No abstract available.
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, Cabello RV, Jauch-Lembach J, Thakur A, Haliduola H, Brueckmann I, Gaylis NB. Wiland P, et al. Among authors: cabello rv. BioDrugs. 2020 Dec;34(6):809-823. doi: 10.1007/s40259-020-00447-6. BioDrugs. 2020. PMID: 33119861 Free PMC article. Clinical Trial.